4SC AG today announced that Yakult Honsha Co. Ltd., 4SC’s development partner for resminostat in Japan, opens additional clinical centers in Japan and contributes patients to the RESMAIN study. Additionally, 4SC received a milestone payment.
by eazee-designstudio
Today Themis and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a partnership under which Themis will provide advanced vaccine development and manufacturing for Lassa fever and MERS. The investment of up to $37,500,000 represents an innovative approach to funding vaccine development, unlocking research and development potential so that vaccines are ready for efficacy studies during an outbreak.
